Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type September 2020 ESMO 2020 Read more
2022 August Health Innovation Artificial Intelligence tool recommends optimal chemotherapy dosage Read more
2022 August ASCO 2022 COVID-19 pandemic impacted on screening and care of patients with rare hereditary cancers Read more
2022 July Cancer trials Long-term benefits from pertuzumab in HER-2 positive breast cancer patients Read more
2022 July Prevention A healthy lifestyle halves risk of dying as a result of prostate cancer in high-risk men Read more
2022 July Cancer trials Encouraging results with tumour-infiltrating lymphocytes as therapy for melanoma patients Read more
2022 July EAU 2022 Surgical treatment update for RCC patients from European urology congress Read more